KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Tax Provisions (2017 - 2025)

Acadia Pharmaceuticals (ACAD) has 9 years of Tax Provisions data on record, last reported at -$27.2 million in Q3 2025.

  • For Q3 2025, Tax Provisions fell 547.29% year-over-year to -$27.2 million; the TTM value through Sep 2025 reached $5.0 million, down 38.73%, while the annual FY2025 figure was -$252.1 million, 897.17% down from the prior year.
  • Tax Provisions reached -$27.2 million in Q3 2025 per ACAD's latest filing, down from $8.8 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $17.3 million in Q4 2024 and bottomed at -$27.2 million in Q3 2025.
  • Average Tax Provisions over 5 years is $1.5 million, with a median of $642500.0 recorded in 2022.
  • Peak YoY movement for Tax Provisions: skyrocketed 2209.52% in 2022, then crashed 833.33% in 2023.
  • A 5-year view of Tax Provisions shows it stood at $189000.0 in 2021, then surged by 339.68% to $831000.0 in 2022, then plummeted by 833.33% to -$6.1 million in 2023, then skyrocketed by 384.59% to $17.3 million in 2024, then plummeted by 256.84% to -$27.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$27.2 million in Q3 2025, $8.8 million in Q1 2025, and $17.3 million in Q4 2024.